By Georgina Mills

Research at the Pirbright Institute has shown that two doses are better than one when vaccinating against Covid-19.

Working with the University of Oxford on its vaccine, Pirbright demonstrated that pigs that received two doses of the ChAdOx1 nCoV-19 vaccine produced a greater antibody response than those receiving a single dose.

A vaccine is seen as a key part of the solution to the global pandemic that has resulted from the emergence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) -- or Covid-19.

ChAdOx1 nCoV-19 was developed by a team of scientists at the Jenner Institute. It is a chimpanzee adenovirus-vectored vaccine that has been engineered to express the spike protein from SARS-CoV2, the protein against which protective antibodies are generated in infected patients.

Phase 1 human clinical trials of the single dose vaccine have already begun following research that showed that macaques were protected against lung disease after a single immunisation.

Volunteers are now being recruited for the next phase of human trials and the university hopes an effective vaccine could be produced as early as later this year.

The studies carried out at Pirbright were designed to establish whether two doses of the new vaccine in pigs (prime and boost) might elicit a greater immune response and therefore be a more effective approach to developing a protective response. Pigs are a useful model having previously been shown to predict vaccine outcome in people, particularly in influenza studies.

> Two doses of the vaccine elicited a significantly greater antibody response in pigs

The results showed that two doses of the vaccine elicited a significantly greater antibody response in pigs. The researchers saw a marked increase in neutralising antibodies, which bind to the virus in a way that blocks infection.

It is not yet known what level of immune response will be required to protect people against SARS-CoV2. Vaccine efficacy trials are underway, and if the efficacy result is lower than hoped for after a single dose, it is important to know if giving two doses could result in a greater immune response, which could then be more protective.

Further research in people is required and currently two doses are being assessed in a small number of clinical trial participants.

Pirbright has also been involved in diagnostic testing for Covid-19. In April, it supplied 13 of its high-throughput testing instruments to the UK's National Coronavirus Testing Centre in Milton Keynes. These machines are usually used in Pirbright's reference laboratories to test for animal diseases such as foot-and-mouth disease, African swine fever and bluetongue.

In addition, over 60 of Pirbright's diagnostic staff and scientists have volunteered to join the testing effort at seven Public Health England testing sites across the country.

Scottish vet labs are helping out with Covid-19 testing too. The Moredun Research Institute and Scotland's Rural College have teamed up to provide extra testing capacity within lab facilities at Pentlands Science Park in Midlothian. Laboratory space and equipment are being repurposed to help the NHS by providing capacity for around 1000 tests a day.

Moredun's specialist high-containment facilities for working with high-hazard group pathogens will allow scientists to safely handle samples for SARS-Cov2 testing while utilising SRUC veterinary labs' capacity to deliver high-throughput PCR testing. The team will be testing for the presence of the virus itself, which indicates whether someone has active virus infection. ●
